Ara
Toplam kayıt 21, listelenen: 1-10
Is the end close for the graft-versus-host disease that is a big problem following allogeneic hematopoetic stem cell transplantation?
(American Society of Hematology, 2018)
…
Real-world data from the Turkish national chronic lymphocytic leukemia registry
(CIG Media Group, 2020)
Objective: We have previously established a nationwide registry to obtain real-world data to document the demographics and treatment outcomes of Turkish CLL patients. Patients or other participants: Patients who were ...
Ibrutinib as a promising treatment for pulmonary complications due to refractory chronic graft versus host disease
(Elsevier Science Inc, 2020)
Introduction: Despite major improvements in allogeneic hematopoetic stem cell transplantation form matched related/ unrelated donor over last decades, chronic graft-versus-host disease (cGVHD) is still the leading cause ...
Artificial intelligence to assist better myeloma care, is it the time?
(Cıg Media Group, 2019)
Myeloma treatment made an enormous progress during the last decade. Armamentarium is grossly enlarging each year in the field of treatment. Parallel to the progress achieved to provide better care for myeloma patients, ...
An interim analysis of the Turkish Myeloma Registry among patients who have received up to two lines of therapy
(CIG Media Group, 2021)
Background To investigate the demographics and treatment details of the myeloma patients who were diagnosed and followed up in Turkey and received up to two lines of therapy. Methods Patients who were recorded on the ...
Turkish acute lymphoblastic leukemia registry, retrospective phase data
(The American Society of Hematology, 2019)
Background and Aim: Significant developments have occurred in clinical management of acute lymphoblastic leukemia (ALL) in adults over recent decades. However, treatment results are still not satisfactory especially in ...
An interim analysis of the Turkish myeloma registry among the patients who have received up to two lines of therapy
(American Society of Hematology, 2021)
...
Adult case series of extramedullary relapsing acute myeloid leukemia (AML) after allogeneic stem cell transplantation in whom a rapid response and a reasonably long remission could be achieved with gemtuzumab ozogamycin (GO)
(The American Society of Hematology, 2019)
Gemtuzumab Ozogamycin (GO) is a drug conjugated monoclonal antibody which targets CD33 an antigen highly expressed on the surface of AML blasts. GO is approved for the treatment of both newly-diagnosed and relapsed AML. ...